

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/251908 A1

(51) International Patent Classification:

G01N 33/50 (2006.01) A61K 35/15 (2015.01)
C12N 5/0787 (2010.01) A61P 7/00 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/SG2021/050342

(22) International Filing Date:

11 June 2021 (11.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202005589P 12 June 2020 (12.06.2020) SG

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: NG, Lai Guan; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). KWOK, Immanuel, Weng Han; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). TAN, De Li, Leonard; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG). GINHOUX, Florent; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06 Immunos, Singapore 138648 (SG).

(74) Agent: DONALDSON & BURKINSHAW LLP; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: NEUTROPHIL PROGENITORS AND RELATED METHODS AND USES

(57) Abstract: There is provided a method of identifying a neutrophil progenitor, the method comprising: determining an expression of at least one biomarker selected from the group consisting of: CD71, LOX-1, CD164, CD112, CD181, TACSTD2, CD11b and CD49d in a cell. In various embodiments, the cell is identified as a neutrophil progenitor when it is determined to have at least one of the following expression profiles: CD71^{hi/+}, LOX-1^{int/lo/-}, CD164^{hi/+}, CD112^{hi/+}, CD181^{int/lo/-}, TACSTD2^{hi/+}, CD11b^{lo/-} and/or CD49d^{int/hi/+}. Also disclosed are a method of sorting and/or separating neutrophil progenitors from a cell population, a composition that is enriched in neutrophil progenitors and related uses and methods.

WO 2021/251908 A1